Analystreport

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com